Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

• Egile Nagusiak: Luigi Gargiulo (Egilea), Luciano Ibba (Egilea), Piergiorgio Malagoli (Egilea), Anna G. Burroni (Egilea), Andrea Chiricozzi (Egilea), Paolo Dapavo (Egilea), Silvia M. Ferrucci (Egilea), Massimo Gola (Egilea), Maddalena Napolitano (Egilea), Michela Ortoncelli (Egilea), Maria T. Rossi (Egilea), Claudio Sciarrone (Egilea), Antonio Costanzo (Egilea), Alessandra Narcisi (Egilea)
• Formatua: Liburua
• Argitaratua: Adis, Springer Healthcare, 2024-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Introduction Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of patients with severe AD after being evaluated in se...